In This Article:
On Thursday, Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents.
Amphastar is a biopharmaceutical company focusing primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products.
The company reported sales of $186.5 million, up 20% year over year, missing the consensus of $188.81 million.
Jack Zhang, Amphastar’s President and Chief Executive Officer, commented, “We are incredibly proud that in 2024, we exceeded our long-term goal of achieving $100 million in annual sales for Primatene MIST, and we look forward to continuing to grow the brand. Furthermore, BAQSIMI showed strong factory sales growth of 12% compared to the fourth quarter of last year. As we look ahead to 2025, we plan to continue developing and growing our proprietary pipeline.”
Primatene MIST exceeded the long-term goal of $100 million in annual sales (around $29 million in the quarter), while BAQSIMI contributed $41.8 million in direct sales during the fourth quarter alone ($126.9 million for the full year).
JP Morgan says the company has seen some setbacks over the past several months, including a competitive approval for glucagon (~15% of Amphastar revenues) and several pipeline delays.
Analyst Ekaterina Knyazkova sees limited downside for the stock as Amphastar shares are now in the low $30s. Primatene MIST and Baqsimi continue growing, with the current valuation reflecting little value for Amphastar’s extensive R&D efforts and pipeline.
JP Morgan maintains the Overweight rating for Amphastar’s stock with a price target of $45.
Price Action: AMPH stock is down 8.35% at $28.86 at the last check Friday.
Read Next:
Photo by Ground Picture on Shutterstock.
Latest Ratings for AMPH
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Piper Sandler | Maintains | Overweight | |
| Jan 2022 | Piper Sandler | Upgrades | Neutral | Overweight |
| Mar 2021 | Wells Fargo | Maintains | Equal-Weight |
View More Analyst Ratings for AMPH
View the Latest Analyst Ratings
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
This article Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.